Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Folia Medica Indonesiana Jurnal Farmasi Klinik Indonesia Majalah Biomorfologi (Biomorphology Journal) Indonesian Journal of Cancer
Heru Purwanto
Division Of Oncology, Department Of Surgery, Faculty Of Medicine, Universitas Airlangga; Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health Other

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Analysis of Antiemetic Premedication Administration Timing on Nausea and Vomiting Incidence among Breast Cancer Patients Receiving Chemotherapy Mahardian Rahmadi; Indira D. Kharismawati; Heru Purwanto; Irvina Harini; Suharjono Suharjono; Chris Alderman
Indonesian Journal of Clinical Pharmacy Vol 9, No 4 (2020)
Publisher : Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15416/ijcp.2020.9.4.298

Abstract

The risk factors affecting chemotherapy-induced nausea and vomiting (CINV) includes antiemetic premedication time pattern, and this study investigates the capability of enhancing this in breast cancer patients receiving high emetogenic chemotherapy (HEC). Furthermore, this observational research was implemented at the oncology unit of Dr. Soetomo General Hospital Surabaya over a three-month period involving 69 female patients. The results showed unspecific antiemetic premedication timing in comparison to those with recommended timeframes, was connected with greater occurrence of both acute nausea in all cycles of chemotherapy (p<0.05), and acute vomiting in second and third cycles (p<0.05) but not in the first cycle (p=0.49). However, specific time administration of antiemetic treatment was linked with lower incidence of delayed nausea in all cycles (p<0.05), and less delayed vomiting in second and third cycles (p<0.05) but not in first cycle (p=0.10). These findings indicate specific time administration of antiemetic drugs causes significant advantages in mitigating CINV among breast cancer patients treated with emetogenic chemotherapy, and significantly lessened the occurrence of acute and delayed nausea and vomiting.Keywords: Antiemetic premedication timing, breast cancer, CINV, nausea and vomiting Analisis Waktu Pemberian Premedikasi Antiemetik terhadap Kejadian Mual Muntah pada Pasien Kanker Payudara yang Mendapatkan Kemoterapi AbstrakKemoterapi dapat menginduksi mual muntah (chemotherapy-induced nausea and vomiting, CINV) yang dipengaruhi oleh beberapa faktor. Salah satu faktornya adalah waktu pemberian premedikasi antiemetik yang dapat meningkatkan kejadian CINV pada pasien kanker payudara yang menerima kemoterapi. Studi ini menganalisis waktu pemberian premedikasi antiemetik terhadap kejadian mual dan muntah yang terjadi pada pasien kanker payudara yang mendapatkan kemoterapi dengan tingkat emetogenik yang tinggi. Penelitian ini merupakan penelitian observasional prospektif dilakukan di Poli Onkologi Satu Atap RSUD Dr. Soetomo Surabaya selama periode pengambilan data tiga bulan dan melibatkan 69 wanita kanker payudara yang mendapat kemoterapi dengan tingkat emetogenik yang tinggi. Pemberian premedikasi antiemetik dengan waktu yang tidak spesifik, meningkatkan kejadian mual akut pada semua siklus dengan p<0,05 dan pada kejadian muntah akut pada siklus kedua dan ketiga (p<0,05), namun tidak pada siklus pertama kemoterapi (p=0,49). Pemberian premedikasi antiemetik dengan waktu spesifik dapat menurunkan kejadian mual tertunda di siklus pertama hingga ketiga (p<0,05) dan pada kejadian muntah tertunda pada siklus kedua dan ketiga (p<0,05), namun tidak pada siklus pertama (p=0,10). Penelitian ini memberikan bukti bahwa premedikasi antiemetik yang diberikan dengan waktu spesifik memberikan manfaat dalam mengurangi kejadian CINV yang berpotensi pada pasien kanker payudara yang mendapatkan kemoterapi dengan tingkat emetogenik tinggi.   Kata kunci: CINV, kanker payudara, mual dan muntah, waktu pemberian premedikasi antiemetik
Faktor Klinis dan Histopatologi serta Hubungannya dengan Kekambuhan Pascaoperasi pada Pasien Kanker Payudara di RSUD Dr. Soetomo, Januari–Juni 2015 KEZIA EVELINE; HERU PURWANTO; PUDJI LESTARI
Indonesian Journal of Cancer Vol 11, No 2 (2017): April - June
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (488.845 KB) | DOI: 10.33371/ijoc.v11i2.502

Abstract

ABSTRACT Breast cancer recurrence occurs because of factors such as surgical problem and clinicopathological features. The present study aimed to assess the relation between clinicopathological factors to breast cancer recurrence. Cross sectional design was used to take medical documents of all patients who visited Out Patient Department Soetomo Hospital from January 2015 to June 2015. A total of 228 patients were identified. The rates of breast cancer recurrence were 30%, most of recurrence occurred in first 5 years and the peak was in the first year. There were significant correlations between breast cancer recurrence and the factors observed below: tumor size [p=0.01,PR(95% CI)=1.621(1.086-2.421)]; nodal status 1-3 and ≥ 4 ≥ 4 [respectively p=0.014,PR(95%CI)=1.281(1.030-2.593) ; p=0.011,PR(95%CI) =1.289(1.038-1.601)]; tumor location [p=0.00,PR(95%CI)=2.422(1.576-3.721)]; hospital where the operation performed [p=0.03,PR(95%CI)=1.207(1.026-1.421)]; adjuvant therapy [p=0.00,PR(95%CI)= 4.371(2.231- 8.566)]. However there were no correlations of breast cancer recurrence and age, clinical stage or type of surgery. Conclusion, there are significant correlations between breast cancer recurrence and clinicopathological factors, such as tumor size, nodal status, tumor location, hospital where the operation performed and adjuvant therapy ABSTRAKKekambuhan kanker payudara terjadi karena beberapa faktor, di antaranya faktor klinis dan histopatologis. Penelitian ini bertujuan untuk mengetahui hubungan faktor klinis dan histopatologi terhadap kekambuhan. Penelitian ini menggunakan desain cross sectional dengan mengambil data dari rekam medis pasien yang berkunjung ke Unit Rawat Jalan RSUD Dr. Soetomo periode Januari- Agustus 2015. Sebanyak 228 pasien diidentifikasi. Tingkat kekambuhan kanker payudarasebsar 30%, sebagian besar kekambuhan terjadi dalam 5 tahun pertama, dan puncaknya adalah pada tahun pertama. Ada hubungan yang signifikan antara kekambuhan kanker payudara dengan faktor-faktor yang diamati: ukuran tumor [p=0,01, PR (95%CI) =1,621 (1.086-2.421)]; status nodal 1-3 and ≥ 4 ≥ 4 [masing-masing p=0,014,,PR(95%CI) = 1.281(1.030-2.593); p=0,011, PR (95%CI) = 1.289(1.038-1.601)]; letak tumor [p=0,00, PR(95%CI) = 2.422(1.576-3.721)]; rumah sakit tempat operasi dilaksanakan[p=0,03, PR,(95%CI)=1.207(1.026-1.421)]; terapi adjuvant [p=0,00, PR(95%CI)= 4.371(2.231-8.566)]. Namun, tidak ada korelasi antara kekambuhan kanker payudara dengan usia, stadium klinis, dan jenis operasi. Kesimpulan, terdapat hubungan yang signifikan antara kekambuhan kanker payudara dengan ukuran tumor, status nodal, lokasi tumor, rumah sakit di mana operasi dilaksanakan, dan terapi adjuvant.
The Implication of Mastectomy Flap Fixation in Decreasing the Incidence of Seroma on Breast Cancer Patient Patric Christ Ardhika Kustono; Heru Purwanto
Folia Medica Indonesiana Vol. 57 No. 4 (2021): December
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (729.987 KB) | DOI: 10.20473/fmi.v57i4.12009

Abstract

Highlight: Modification of radical mastectomy with flap fixation treatment in seroma production in breast cancer patients was analyzed.The number of seromas from the drain removal time in patients undergoing modified radical mastectomy with flap fixation was reduced. Abstract: Seroma is the most common complication after mastectomy procedure. This study was conducted to analyse the treatment of flap fixation in seroma production after modified radical mastectomy in breast cancer patients.  An interventional prospective clinical study in 35 female patients with breast cancer who underwent modified radical mastectomy with flap fixation in the period August-December 2018 and 35 patients without flap fixation through historical data of patient who underwent modified radical mastectomy in the period 2016-2017 at RSUD Dr. Soetomo Surabaya. Data of characteristic patients will be presented descriptively and analyzed statistically using the appropriate test.  The result of the statistical test using Chi Square with a 95% significance level obtained a value of p = 0.000 (p <0.05), it was said statistically that there was a significant relationship between the treatment of flap fixation and the time of releasing drain in this study. The treatment of flap fixation will reduce drainage time by <10 days. The results of the odds ratio (OR) obtained OR = 16 and CI: 95% (4.094 – 62.528) which means that the treatment of flap fixation will reduce the releasing time of the drain 16 times more effectively than not performing flap fixation. Correlation between the treatment of flap fixation and the time of releasing drain was considered to be moderately positive (Contingency Coefficient Chi Square = 0.476). There was a significant reduction in the number of seroma assessed from the time of releasing drain faster in patients who underwent modified radical mastectomy with flap fixation.
GLUCOSE LEVELS OF PLEURAL EFFUSION FLUID AND HER2 STATUS IN PLEURAL-METASTATIC BREAST CANCER Muhammad Dhanny Irawan; Desak Gede Agung Suprabawati; Heru Purwanto
Majalah Biomorfologi Vol. 33 No. 2 (2023): MAJALAH BIOMORFOLOGI
Publisher : Universitas Airlangga, Surabaya, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/mbiom.v33i2.2023.75-81

Abstract

Highlights Patients with breast cancer who have distant metastases are frequently impacted by pleural effusion. HER2 status was found to be substantially correlated with glucose levels in pleural effusion fluid. Abstract Background: Patients diagnosed with breast cancer who have also been affected by distant metastases often suffer from pleural effusion. The prognosis of malignant pleural effusions worsens when glucose levels in the pleural fluid are low. Elevated levels of anaerobic glycolysis due to HER2 overexpression cause breast cancer cells to take in more glucose. Objective: This study aimed to identify any correlation between glucose levels in pleural fluid and HER2 status in breast cancer patients. Material and Method: In this research, 35 female patients with thoracocentesis pleural metastatic breast cancer participated in an analytical observational study using a cross-sectional design. Patients who had undergone thoracocentesis had their HER2 status determined based on the information included in their medical records in the Integrated Oncology Clinic (Poli Onkologi Satu Atap (POSA)) Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. After obtaining data on glucose levels in pleural fluid and HER2 status, statistical analysis was carried out to determine the relationship between the two parameters. Results: The statistical test results with a 95% significance level obtained p=0.004 (p<0.05), so it could be statistically said that there was a significant relationship between the glucose level of pleural fluid effusion with HER2 status. The obtained OR values were 10.93 and CI=95% (1.87-63.97), so that it could be interpreted that the low-glucose levels of pleural effusion fluid increase the proportion of patients with positive HER2 compared to not low-glucose levels of pleural effusion fluid. The correlation between the glucose level of pleural effusion fluid and HER2 status was moderately positive (Chi-Square Contingency Coefficient = 0.44). Conclusion: Glucose levels in pleural effusion fluid were significantly correlated with HER2 status.
Co-Authors Alphania Rahniayu Chris Alderman Indira D. Kharismawati Irvina Harini KEZIA EVELINE Mahardian Rahmadi Muhammad Dhanny Irawan Patric Christ Ardhika Kustono Pudji Lestari Raniah Baswedan Suharjono, Suharjono Suprabawati, Desak Gede Agung